Italy bans 7 APIs from compounding pharmacies after off-label abuse

By Fiona BARRY

- Last updated on GMT

Compounding pharmacies in Italy have been banned from working with certain APIs.
Compounding pharmacies in Italy have been banned from working with certain APIs.
The Italian Ministry of Health has banned compounding pharmacies from preparing drugs containing any of seven APIs after chemists were discovered making dangerous off-label weight loss treatments.

The decree affects “abuses​” of the following active pharmaceutical ingredients:

  • TRIAC/tiratricol ​for thyroid problems and weight loss;
  • the antidepressants fluoxetine​ and bupropion​;
  • clorazepate​, a benzodiazepine;
  • furosemide​, a diuretic;
  • metformin​, for diabetes;
  • and the anticonvulsant topiramate​.

The ban, backed by the Italian Drug Agency (AIFA), comes after some compounding pharmacies created unregistered slimming drugs from combinations of APIs not intended for weight control.

Patients reported adverse reactions to the country’s pharmacovigilance network, and AIFA said such drugs “have an extremely unfavourable risk-benefit ratio and can be dangerous for those who use them.​”

The risk of adverse reactions goes up with the number of APIs in the drug preparation, the Ministry of Health added, saying the ingredients on its banned list can cause psychiatric and cardiovascular reactions.

Additionally, these combinations have never been tested in regular clinical trials, and lack the leaflet and information sheet to which the patient can refer to learn about the product​. The documentation available on the individual API does not guarantee its safety when administered in combination with another​”

The move follows two other decrees adopted by AIFA and the Health Minister in May and July which banned phenylpropanolamine/norephedrine and pseudoephedrine in diet drugs.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Products

View more

Webinars